From each FDA label

Do GLP-1s cause a rash?

Wegovy, Ozempic, Rybelsus/Ozempic tablets, Saxenda, Victoza and Byetta list it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Word for word

What each label says about a rash or itching

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • In clinical trials in adults for weight reduction, 1.4% of Wegovy-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation).
  • In a pediatric clinical trial for weight reduction, rash was reported in 3% of Wegovy-treated patients and 0% of placebo-treated patients, and urticaria was reported in 3% of Wegovy-treated patients and 0% of placebo-treated patients.

Label revised Jun 18, 2026. DailyMed

Zepbound

  • The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching).

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • Hypersensitivity reactions have been reported with Mounjaro in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of Mounjaro-treated patients compared to 1.7% of placebo-treated patients.

Label revised Aug 27, 2026. DailyMed

Trulicity

  • Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on Trulicity in clinical studies.
  • In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of Trulicity-treated patients and in 0.0% of placebo-treated patients.

Label revised Jun 16, 2026. DailyMed

Saxenda

  • The most common reactions, each reported by 1% to 2.5% of Saxenda-treated patients and more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site.
  • Urticaria was reported in 0.7% of Saxenda-treated patients and 0.5% of placebo-treated patients.

Label revised Feb 25, 2026. DailyMed

Victoza

  • Injection site reactions (e.g., injection site rash, erythema) were reported in approximately 2% of Victoza-treated adult patients in the five double-blind, glycemic control trials of at least 26 weeks duration.

Label revised Oct 14, 2025. DailyMed

Ozempic, Rybelsus and Ozempic tablets, Byetta: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Foundayo: no finding on this in the sections read here.

Not from trials

Reports to FDA about a rash or itching

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicItching: 1,164 · Rash: 1,029 · Urticaria: 364 · Rash pruritic: 176 · Rash erythematous: 87 · Rash macular: 7670,863
TrulicityRash: 884 · Itching: 825 · Urticaria: 403 · Rash pruritic: 152 · Rash erythematous: 63 · Rash macular: 4587,279
MounjaroItching: 830 · Rash: 828 · Urticaria: 473 · Rash pruritic: 143 · Rash erythematous: 85 · Rash macular: 5797,440
ZepboundItching: 587 · Rash: 585 · Urticaria: 399 · Rash pruritic: 121 · Rash erythematous: 66 · Rash macular: 3180,835
VictozaRash: 557 · Itching: 533 · Urticaria: 308 · Rash pruritic: 91 · Rash erythematous: 31 · Rash macular: 2941,462
ByettaItching: 477 · Urticaria: 383 · Rash: 366 · Rash pruritic: 144 · Rash erythematous: 35 · Rash macular: 2752,087
WegovyItching: 285 · Rash: 283 · Urticaria: 128 · Rash pruritic: 37 · Rash erythematous: 29 · Rash macular: 1525,993
Rybelsus and Ozempic tabletsRash: 180 · Itching: 126 · Urticaria: 51 · Rash pruritic: 25 · Rash erythematous: 13 · Rash macular: 47,758
SaxendaRash: 117 · Itching: 73 · Urticaria: 68 · Rash pruritic: 16 · Rash erythematous: 57,270
FoundayoItching: 22 · Rash: 22 · Urticaria: 13 · Rash pruritic: 9 · Rash erythematous: 33,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Rash and itching on a GLP-1: common questions

Does Wegovy cause a rash?

Its FDA label: In clinical trials in adults for weight reduction, 1.4% of Wegovy-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation). In a pediatric clinical trial for weight reduction, rash was reported in 3% of Wegovy-treated patients and 0% of placebo-treated patients, and urticaria was reported in 3% of Wegovy-treated patients and 0% of placebo-treated patients.

Does Zepbound cause a rash?

Its FDA label: The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching).

Does Mounjaro cause a rash?

Its FDA label: Hypersensitivity reactions have been reported with Mounjaro in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of Mounjaro-treated patients compared to 1.7% of placebo-treated patients.

Does Trulicity cause a rash?

Its FDA label: Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on Trulicity in clinical studies. In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of Trulicity-treated patients and in 0.0% of placebo-treated patients.

Does Saxenda cause a rash?

Its FDA label: The most common reactions, each reported by 1% to 2.5% of Saxenda-treated patients and more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site. Urticaria was reported in 0.7% of Saxenda-treated patients and 0.5% of placebo-treated patients.

Does Victoza cause a rash?

Its FDA label: Injection site reactions (e.g., injection site rash, erythema) were reported in approximately 2% of Victoza-treated adult patients in the five double-blind, glycemic control trials of at least 26 weeks duration.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.